Ropes & Gray advised Foghorn Therapeutics Inc. on the offering, and Latham & Watkins advised the underwriters. Foghorn Therapeutics Inc. (Nasdaq: FHTX) (“Foghorn”), a clinical-stage biotechnology...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here